O
DRNA

OrbiMed’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

OrbiMed’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-141,900
Closed -$1.98M – 142
2015
Q2 		$1.98M Sell
141,900
-53,100
-27% -$974K 0.02% 130
2015
Q1 		$4.69M Buy
+195,000
New +$4.39M 0.04% 119

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

OrbiMed's DRNA Position: Q3 2015 in Review

OrbiMed sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2015, closing a stake of 141,900 shares — an estimated $1.98M sold.

OrbiMed first reported a position in DRNA in Q1 2015 and held it in 2 quarters. The position peaked at $4.69M in Q1 2015. 51 funds tracked by Wall St. Rank hold DRNA as of Q3 2015.

  • OrbiMed reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • OrbiMed sold 141,900 Dicerna Pharmaceuticals, Inc. shares in Q3 2015, an estimated $1.98M.
  • OrbiMed first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • OrbiMed's Dicerna Pharmaceuticals, Inc. position peaked at $4.69M in Q1 2015.
  • 51 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2015.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.